These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 21702122)

  • 21. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
    Sfikakis PP; Boletis JN; Tsokos GC
    Curr Opin Rheumatol; 2005 Sep; 17(5):550-7. PubMed ID: 16093832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current role of rituximab in systemic lupus erythematosus.
    Mok CC
    Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
    Reddy V; Cambridge G; Isenberg DA; Glennie MJ; Cragg MS; Leandro M
    Arthritis Rheumatol; 2015 May; 67(8):2046-55. PubMed ID: 25916583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.
    Tanaka Y; Yamamoto K; Takeuchi T; Nishimoto N; Miyasaka N; Sumida T; Shima Y; Takada K; Matsumoto I; Saito K; Koike T
    Mod Rheumatol; 2007; 17(3):191-7. PubMed ID: 17564773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [What's new in internal medicine: emerging treatments for systemic lupus erythematosus].
    Hachulla É
    Ann Dermatol Venereol; 2011 Dec; 138 Suppl 4():S241-4. PubMed ID: 22202645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Connective tissue diseases: The conundrum of B cell depletion in SLE.
    Sanz I
    Nat Rev Rheumatol; 2009 Jun; 5(6):304-5. PubMed ID: 19491910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
    Rossi EA; Chang CH; Goldenberg DM
    PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
    Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
    Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B; Lindholm C; Pullerits R
    Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG; Jones RB; Burns SM; Jayne DR
    Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis.
    Duxbury B; Combescure C; Chizzolini C
    Lupus; 2013 Dec; 22(14):1489-503. PubMed ID: 24135078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B cell depletion therapy in systemic lupus erythematosus.
    Anolik J; Sanz I; Looney RJ
    Curr Rheumatol Rep; 2003 Oct; 5(5):350-6. PubMed ID: 12967516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy.
    Tsai MJ; Chou CW; Lin FC; Chang SC
    Lupus; 2012 Jul; 21(8):914-8. PubMed ID: 22287506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
    Kneitz C; Wilhelm M; Tony HP
    Immunobiology; 2002 Dec; 206(5):519-27. PubMed ID: 12607727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B cell depletion in lupus and Sjögren's syndrome: an update.
    Coca A; Sanz I
    Curr Opin Rheumatol; 2009 Sep; 21(5):483-8. PubMed ID: 19644378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of recurrent pancreatitis secondary to systemic lupus erythematosus with B-cell depletion therapy.
    Al-Musawi ZS; Nabar UJ
    Arch Iran Med; 2011 Jan; 14(1):66-70. PubMed ID: 21194267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case].
    Sabugo F; Llanos C; Soto L; Gutiérrez J; Cuchacovich M
    Rev Med Chil; 2005 Jun; 133(6):681-4. PubMed ID: 16075133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B-cell targeted treatments for lupus: the journey counts as much as the destination.
    Falgarone G; Dhote R; Boissier MC
    Joint Bone Spine; 2012 Oct; 79(5):437-40. PubMed ID: 22480746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.
    Hui-Yuen JS; Nguyen SC; Askanase AD
    Lupus; 2016 Sep; 25(10):1086-96. PubMed ID: 27497253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.